Appendix A: Guidelines Reviewed

1. Hoffmann T, Glasziou P, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ.* 2014;348:g1687.

2. Dwan K, Li T, Altman DG, et al. CONSORT 2010 statement: extension to randomised crossover trials. *BMJ.* 2019;366:I4378.

3. Juszczak E, Altman DG, Hopewell S, et al. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. *JAMA.* 2019;321(16):1610-1620.

4. Hemming K, Taljaard M, McKenzie JE, et al. Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration. *BMJ.* 2018;363:K1614.

5. Montgomery P, Grant S, Mayo-Wilson E, et al. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. *Trials.* 2018;19(1):407.

6. Welch VA, Norheim OF, Jull J, et al. CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials. *BMJ.* 2017;359:J5085.

7. Pandis N, Chung B, Scherer RW, et al. CONSORT 2010 statement: extension checklist for reporting within person randomised trials. *BMJ.* 2017;357:J2835.

8. Cheng C-W, Wu TX, Shang HC, et al. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. *Ann Intern Med.* 2017.

9. Pandis N, Fleming PS, Hopewell S, et al. The CONSORT Statement: Application within and adaptations for orthodontic trials. *American Journal of Orthodontics and Dentofacial Orthopedics* 2015;147(6):663-679.

10. Vohra S, Shamseer L, Sampson M, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement. *Brit J Anaesth.* 2015;350:h1738.

11. Bravo E, Calzolari A, De Castro P, et al. Developing a guideline to standardize the citation of bioresources in journal articles (CoBRA). *BMC Med.* 2015;13:33.

12. Jenkins PA, Carroll JD. How to report low-level laser therapy (LLLT)/photomedicine dose and beam parameters in clinical and laboratory studies. *Photomedicine and Laser Surgery* 2011;29(12):785-787.

13. Meyer E, Delaney M, Lin Y, et al. A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative. *Transfusion.* 2013;53(6):1328-1334.

14. Stiles CR, Biondo PD, Cummiong G, et al. Clinical Trials focusing on cancer pain educational interventions: Core components to include during planning and reporting. *J Pain Symptom.* 2010;40(2):301-308.

15. Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. *Annals of the Rheumatic Diseases* 2008;67(10):1360-1364.

16. Helmhout PH, Staal JB, Maher CG, et al. Exercise therapy and low back pain: insights and proposals to improve the design, conduct, and reporting of clinical trials. *Spine.* 2008;33(16):1782-1788.

17. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. *J Clin Oncol.* 2004;22(3):537-556.

18. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. *Leukemia.* 2012;26(11):2317-2325.

19. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood.* 2010;115(3):453-474.

20. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *J Clin Oncol.* 2003;21(24):4642-4649.

21. Rochon PA, Hoey J, Chan AW, et al. Financial Conflicts of Interest Checklist 2010 for clinical research studies. *OpenMed.* 2010;4(1):e69-91.

22. Schriger DL. Suggestions for improving the reporting of clinical research: the role of narrative. *Annals of Emergency Medicine.* 2005;45(4):437-443.

23. Pocock SJ, Travison TG, Wruck LM. Figures in clinical trial reports: current practice & scope for improvement. *Trials.* 2007;8:36.

24. Kent DM, Rothwell PM, Ioannidis JP, et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. *Trials.* 2010;11:85.

25. Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine--reporting of subgroup analyses in clinical trials. *New Engl J Med.* 2007;357(21):2189-2194.

26. Yong MY, González-Beltrán A, Begent R. Establishing a knowledge trail from molecular experiments to clinical trials. *New Biotechnology* 2011;28(5):464-480.

27. Hrynaszkiewicz I, Norton ML, Vickers AJ, et al. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. *BMJ.* 2010.

28. Leech NL, Onwuegbuzie AJ. Guidelines for conducting and reporting mixed research in the field of counseling and beyond. *Journal of Counseling and Development.* 2010;88(1):61-69.

29. Stock-Schroer B, Albrecht H, Betti L, et al. Reporting experiments in homeopathic basic research (REHBaR) - a detailed guideline for authors. *Homeopathy.* 2009;98(4):287-298.

30. Welch RW, Antoine JM, Berta JL, et al. Guidelines for the design, conduct and reporting of human intervention studies to evaluate the health benefits of foods. *British Journal of Nutrition* 2011;106:S3-15.

31. Berger ML, Mamdani M, Atkins D, et al. Good research practices for comparative effectiveness research: Defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: The ISPOR good research practices for retrospective database analysis task force report - Part i. *Value Health.* 2009;12(8):1044-1052.

32. Reeves BC, W G. Guidelines for reporting non-randomised studies. *Forsch Komplementarmed Klass Naturheilkd.* 2004;11:46-52.

33. Vickers AJ, Ballen V, Scher HI. Setting the bar in phase II trials: the use of historical data for determining “go/no go” decision for definitive phase III testing. *Clinical Cancer Research* 2007;13(3):972-976.

34. Chang S, Vogelbaum M, Lang FF, et al. GNOSIS: Guidelines for Neuro-Oncology: Standards for Investigational Studies - reporting of surgically based therapeutic clinical trials. *Journal of Neurooncology.* 2007;82(2):211-220.

35. Lee CW, Chi KN. The standard of reporting of health-related quality of life in clinical cancer trials. *J Clin Epidemiol.* 2000;53(5):451-458.

36. Fernandes RM, H vdLJ, Offringa M. A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials. *BMC Pediatrics.* 2009;9:77.

37. Dechartres A, Boutron I, Roy C, et al. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. *J Clin Epidemiol.*62(7):695-702.

38. Baker TB, Gustafson DH, Shaw B, et al. Relevance of CONSORT reporting criteria for research on eHealth interventions. *Patient Educ Couns.* 2010;81:S77-86.

39. Robb SL, Carpenter JS, Burns DS. Reporting Guidelines for Music-based Interventions. *Journal of Health Psychology.* 2011;16(2):342-352.

40. Rauch F, Sievanen H, Boonen S, et al. Reporting whole-body vibration intervention studies: recommendations of the International Society of Musculoskeletal and Neuronal Interactions. . *Journal of Musculoskeletal and Neuronal Interactions* 2010;10(3):193-198.

41. Harrington NG, Noar SM. Reporting standards for studies of tailored interventions. *Health Education Research* 2012;27(2):331-342.

42. Dean ME, Coulter MK, Fisher P, et al. Reporting data on homeopathic treatments (RedHot): A supplement to CONSORT. *Research in Complementary Medicine.* 2006;13(6):368-371.

43. Moberg-Mogren E, Nelson D. Evaluating the quality of reporting occupational therapy randomized controlled trials by expanding the CONSORT criteria. *AM J Occup Ther.* 2006;60(2):226-235.

44. Scott SD, Albrecht L, O'Leary K, et al. Systematic review of knowledge translation strategies in the allied health professions. *Implement Sci.* 2012;7:70.

45. Davidson KW, Goldstein M, Kaplan RM, et al. Evidence-based behavioral medicine: what is it and how do we achieve it? *Ann Behav Med.* 2003;26(3):161-171.

46. Saint-Raymond A, Hill S, Martines J, et al. CONSORT 2010. *Lancet.* 2010;376(9737):229-230.

47. Bousquet PJ, Brozek J, Bachert C, et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. *Allergy.* 2009;64(12):1737-1745.

48. Stone SP, Cooper BS, Kibbler CC, et al. The ORION statement: guidelines for transparent reporting of Outbreak Reports and Intervention studies Of Nosocomial infection. *Journal of Antimicrobial Chemotherapy* 2007 59(5):833-840.

49. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood.* 2011;117(18):4691-4695.

50. Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. *BMJ.* 2011;342:d1548.

51. Chang SM, Reynolds SL, Butowski N, et al. GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials. *Neuro-Oncology* 2005;7(4):425-434.

52. Applebaum M, Cooper H, Kline RB, et al. Journal Article Reporting Standards for Quantitative Research in Psychology: The APA Publications and Communications Board Task Force Report *AM Psychol.* 2018 73(1):3-25.

53. Conn VS. Unpacking the Black Box: Countering the problem of inadequate intervention descriptions in research reports. *West J Nurs Res.* 2012 34(4):427-433.

54. Gutman SA. Reporting standards for intervention effectiveness studies. *Am J Occup Ther.* 2010;64(4):523-527.

55. Guise JM, Butler ME, Chang C, et al. AHRQ series on complex intervention systematic reviews—paper 6: PRISMA-CI extension statement and checklist. *J Clin Epidemiol.* 2017;90:43-50.

56. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. *BMJ.* 2015;351:h5527.

57. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207.

58. Kostoulas P, Nielsen SS, Branscum AJ, et al. STARD-BLCM: Standards for the Reporting of Diagnostic accuracy studies that use Bayesian Latent Class Models. *Preventive Veterinary Medicine* 2017;138:37-47.

59. Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ.* 2016:355.

60. Ioannidis JPA, Evans SJW, Gotzsche PC, et al. Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement. *Ann Intern Med.* 2004;141(10):781-788.

61. Eysenbach G, CONSORT EG. CONSORT-EHEALTH: improving and standardizing evaluation reports of Web-based and mobile health interventions. *Journal of Medical Internet Research* 2011;13(4):e126.

62. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. *JAMA.* 2013;309(8):814-822.

63. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: An extension of the CONSORT statement. *BMJ.* 2008 11(337):a2390.

64. Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomised trials in journal and conference abstracts. *Lancet.* 2008;371(9609):281-283.

65. Boutron I, Altman DG, Moher D, et al. CONSORT statement for randomized trials of nonpharmacologic treatments: A 2017 update and a CONSORT extension for nonpharmacologic trial abstracts. *Ann Intern Med.* 2017;167(1):40-47.

66. Gagnier JJ, Boon H, Rochon P, et al. Reporting randomized, controlled trials of herbal interventions: An elaborated CONSORT Statement. *Ann Intern Med.* 2006;144.

67. Campbell MK, Piaggio G, Elbourne DR, et al. Consort 2010 statement: extension to cluster randomised trials. *BMJ.* 2012;345:e5661.

68. Piaggio G, Elbourne DR, Pocock SJ, et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. *JAMA.* 2012;308(24):2594-2604.

69. MacPherson H, Altman DG, Hammerschlag R, et al. Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): Extending the CONSORT Statement. *PLoS Medicine.* 2010;7(6):e1000261.

70. Huria T, Palmer SC, Pitama S, et al. Consolidated criteria for strengthening reporting of health research involving indigenous peoples: the CONSIDER statement. *BMC Medical Research Methodology.* 2019;19(1):173.

71. Gewandter JS, Eisenach JC, Gross RA, et al. Checklist for the preparation and review of pain clinical trial publications: a pain-specific supplement to CONSORT. *Pain Reports.* 2019;4(3):e621.

72. Turner P, Fox-Lewis A, Shrestha P, et al. Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data. *BMC Med.* 2019;17(1):70.

73. Keith MG, Tay L, Harms PD. Systems Perspective of Amazon Mechanical Turk for Organizational Research: Review and Recommendations. *Front Psychol.* 2017;8:1359.

74. De Geest S, Zullig LL, Dunbar-Jacob J, et al. ESPACOMP Medication Adherence Reporting Guideline (EMERGE). *Ann Intern Med.* 2018;169(1):30-35.

75. Yousafzai AK, Aboud FE, Nores M, et al. Reporting guidelines for implementation research on nurturing care interventions designed to promote early childhood development. *Annals of the New York Academy of Sciences.* 2018;1419(1):26-37.

76. Campbell M, Katikireddi SV, Hoffmann T, et al. TIDieR-PHP: a reporting guideline for population health and policy interventions. *BMJ.* 2018;361:k1079.

77. Walker MF, Hoffmann TC, Brady MC, et al. Improving the development, monitoring and reporting of stroke rehabilitation research: Consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable. *Neurorehabil Neural Repair.* 2017;31(10-11):877-884.

78. Stamp LK, Morillon MB, Taylor WJ, et al. Variability in the reporting of serum urate and flares in gout clinical trials: Need for minimum reporting requirements. *The Journal of Rheumatology.* 2018;45(3):419-424.

79. Saito M, Gilder ME, Nosten F, et al. Methodology of assessment and reporting of safety in anti-malarial treatment efficacy studies of uncomplicated falciparum malaria in pregnancy: a systematic literature review. *Malaria Journal.* 2017;16(1):491.

80. Sepucha KR, Abhyankar P, Hoffman AS, et al. Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist. *BMJ Quality and Safety.* 2017;27(5):380-388.

81. Gamble C, Krishan A, Stocken D, et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. *JAMA.* 2017;318(23):2337-2343.

82. Sechopoulos I, Rogers DWO, Bazalova-Carter M, et al. RECORDS: Improved reporting of Monte Carlo Radiation transport studies: Report of the AAPM Research Committee Task Group 268. *Medical Physics.* 2018 45(1):e1-e5.

83. Hakoum MB, Jouni N, Abou-Jaoude EA, et al. Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance. *BMJ Open.* 2017;7(10):e015997.

84. Staniszewska S, Simera I, Seers K, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. *BMJ.* 2017;3:358.

85. Harbin CCWG, Conference C, Legro RS, et al. Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement. *Human Reproduction.* 2014;29(10):2075-2082.

86. Page P, Hoogenboom B, Voight M. Improving the reporting of therapeutic exercise interventions in rehabilitation research. *International Journal of Sports Physical Therapy.* 2017;12(2):297-304.

87. Mistry P, Dunn JA, Marshall A. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines. *BMC Medical Research Methodology* 2017;17(1):108.

88. Murray IR, Geeslin AG, Goudie EB, et al. Minimum information for studies evaluating biologics in orthopaedics (MIBO):Platelet-rich plasma and mesenchymal stem cells. *The Journal of Bone and Joint Surgery. American volume.* 2017;99(10):809-819.

89. Nichols TE, Das S, Eickhoff SB, et al. Best practices in data analysis and sharing in neuroimaging using MRI. *Nat Neurosci.* 2017;20(3):299-303.

90. Steele J, Fisher J, Giessing J, et al. Clarity in reporting terminology and definitions of set end points in resistance training. *Muscle Nerve.* 2017;56(3):368-374.

91. Baldwin SA, Larson MJ. An introduction to using Bayesian linear regression with clinical data. *Behaviour Research and Therapy.* 2017;98:58-75.

92. Groeneweg R, Rubinstein SM, Oostendorp RA, et al. Guideline for reporting interventions on spinal manipulative therapy: Consensus on Interventions Reporting Criteria List for Spinal Manipulative Therapy (CIRCLe SMT). *Journal of Manipulative and Physiological Therapeutics* 2017;40(2):61-70.

93. Pinnock H, Barwick M, Carpenter CR, et al. Standards for Reporting Implementation Studies (StaRI) statement. *BMJ.* 2017;356(i6795).

94. Slade SC, Dionne CE, Underwood M, et al. Consensus on exercise reporting template (CERT): Modified delphi study. *Phys Ther.* 2016;96(10):1514-1524.

95. Kirkham JJ, Gorst S, Altman DG, et al. Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. *PLoS Medicine.* 2016;13(10):e1002148.

96. Des Jarlais DC, Lyles C, Crepaz N, et al. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. *American Journal of Public Health.* 2004(3):361-366.

97. Messiou C, Bonvalot S, Gronchi A, et al. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging. *European Journal of Cancer.* 2016;56:37-44.

98. Provenzano E, Bossuyt V, Viale G, et al. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. *Modern Pathology.* 2015;28(9):1185-1201.

99. Campana LG, Clover AJ, Valpione S, et al. Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. *Radiology and Oncology* 2016;50(1):1-13.

100. Padhani AR, Lecouvet FE, Tunariu N, et al. METastasis reporting and data system for prostate cancer: Practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. *European Urology* 2017;70(1):81-92.

101. Reeve BB, McFatrich M, Pinheiro LC, et al. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative. *Pediatric Blood Cancer.* 2017;64(3).

102. Lineberry N, Berlin JA, Mansi B, et al. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. *BMJ.* 2016;355:i5078.

103. Phillips AC, Lewis LK, McEvoy MP, et al. Development and Validation of the Guideline for Reporting Evidence-Based Practice Educational Interventions and Teaching (GREET). *BMC Medical Education* 2016;16(1):237.

104. Breuer E, Lee L, De Silva M, et al. Using theory of change to design and evaluate public health interventions: a systematic review. *Implement Sci.* 2016;11:63.

105. Cheng A, Kessler D, Mackinnon R, et al. Reporting Guidelines for Health Care Simulation Research: Extensions to the CONSORT and STROBE Statements. *Simulation in Healthcare* 2016;11(4):238-248.

106. Creinin MD, Chen MJ. Medical abortion reporting of efficacy: the MARE guidelines. *Contraception.* 2016;94(2):97-103.

107. Tate RL, Perdices M, Rosenkoetter U, et al. The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement. *Phys Ther.* 2016;96(7):e1-e10.

108. Vanhie A, Meuleman C, Tomassetti C, et al. Consensus on Recording Deep Endometriosis Surgery: the CORDES statement. *Human Reproduction.* 2016;31(6):1219-1223.

109. Hamilton S, Bernstein AB, Blakey G, et al. Developing the clarity and openness in reporting: E3-based (CORE) reference user manual for creation of clinical study reports in the era of clinical trial transparency. *Research Integrity and Peer Review.* 2016 3(1):4.

110. Rosenthal R, Hoffmann H, A CP, et al. Definition and classification of intraoperative complications (CLASSIC): Delphi study and pilot evaluation. *World J Surg.* 2015;39(7):1663-1671.

111. Brethauer SA, Kim J, El Chaar M, et al. Standardized outcomes reporting in metabolic and bariatric surgery. *Surgery for Obesity and Related Diseases.* 2015;11(3):489-506.

112. Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. *Cytometry Part B: Clinical Cytometry* 2016;90(1):31-39.

113. Cook JA, Hislop J, Altman DG, et al. Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers. *Trials.* 2015;16:12.

114. Agarwal S, LeFevre AE, Lee J, et al. Guidelines for reporting of health interventions using mobile phones: mobile health (mHealth) evidence reporting and assessment (mERA) checklist. *BMJ.* 2016;352:i1174.

115. Smith SM, Hunsinger M, McKeown A, et al. Quality of pain intensity assessment reporting: ACTTION systematic review and recommendations. *Journal of Pain.* 2015;16(4):299-305.

116. Boursier J, de Ledinghen V, Poynard T, et al. An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. *Journal of Hepatology* 2015;62(4):807-815.

117. Dykstra K, Mehrotra N, Tornøe CW, et al. Reporting guidelines for population pharmacokinetic analyses. *Journal of Pharmacokinet and Pharmacodyn.* 2015;42(3):301-314.

118. Khanal S, Burgon J, Leonard S, et al. Recommendations for the improved effectiveness and reporting of telemedicine programs in developing countries: Results of a systematic literature review. *Telemed J E Health.* 2015;21(11):903-915.

119. Witkiewitz K, Finney JW, Harris AH, et al. Guidelines for the reporting of treatment trials for alcohol use disorders. *Alcoholism Clinical and Experimental Research* 2015;39(9):1571-1581.

120. Omulo S, Thumbi SM, Njenga MK, et al. A review of 40 years of enteric antimicrobial resistance research in Eastern Africa: what can be done better? . *Antimicrobial Resistance and Infection Control.* 2015;4:1.

121. Rotta I, Salgado TM, Felix DC, et al. Ensuring consistent reporting of clinical pharmacy services to enhance reproducibility in practice: an improved version of DEPICT. *Journal of Evaluation in Clinical Practice* 2015;21(4):584-590.

122. Boller M, Fletcher DJ, Brainard BM, et al. Utstein-style guidelines on uniform reporting of in-hospital cardiopulmonary resuscitation in dogs and cats. A RECOVER statement. *Journal of Veterinary Emergency & Critical Care* 2016;26(1):11-34.

123. Madurasinghe VW, Eldridge S, on behalf of MRC START Group, Forbes G, on behalf of the START Expert Consensus Group. Guidelines for reporting embedded recruitment trials. *Trials.* 2016;17(1):27.

124. Borek AJ, Abraham C, Smith JR, et al. A checklist to improve reporting of group-based behaviour-change interventions. *BMC Public Health 15.* 2015;15(1):963.

125. Moore CM, Kasivisvanathan V, Eggener S, et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. *European Urology* 2013;64(4):544-552.

126. Akard LP, Wang YL. Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners. *Clinical Lymphoma, Myeloma & Leukemia* 2011;11(5):385-395.

127. Higginson IJ, Evans C, J, Grande G, et al. Evaluating complex interventions in end of life care: the MORECare statement on good practice generated by a synthesis of transparent expert consultations and systematic reviews. *BMC Med.* 2013;24(11):111.

128. Kanji S, Hayes M, Ling A, et al. Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. *Clin Pharmacokinet.* 2015 [Epub ahead of print].

129. Biering-Sørensen F, Charlifue S, Devivo MJ, et al. Using the Spinal Cord Injury Common Data Elements. *Topics in Spinal Cord Injury Rehabilitation* 2012;18(1):23-27.

130. Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research *Pharmacoepidemiology and Drug Safety* 2010;19(6):537-554.

131. Duffis EJ, Gandhi CD, Prestigiacomo CJ, et al. Head, neck, and brain tumor embolization guidelines. *Journal of NeuroInterventional Surgery* 2012;4(4):251-255.

132. Froud R, Eldridge S, Kovacs F, et al. Reporting outcomes of back pain trials: a modified Delphi study. *Eur J Pain.* 2011;15(10):1068-1074.

133. Fumagalli D, Bedard PL, Nahleh Z, et al. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. *Lancet Oncology.* 2012;13(6):e240-248.

134. Gershman MD, Staples JE, Bentsi-Enchill AD, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. *Vaccine.* 2012;30(33):5038-5058.

135. Guilhot J, Baccarani M, Clark RE, et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. *Blood.* 2012;119(25):5963-5971.

136. Gurgel RK, Jackler RK, Dobie RA, et al. A new standardized format for reporting hearing outcome in clinical trials. *Journal of Otolaryngology – Head & Neck Surgery.* 2012;147(5):803-807.

137. Hagen NA, Wu JS, Stiles CR. A proposed taxonomy of terms to guide the clinical trial recruitment process. *J Pain Symptom.* 2010;40(1):102-110.

138. Jayaraman MV, Meyers PM, Derdeyn CP, et al. Reporting standards for angiographic evaluation and endovascular treatment of cerebral arteriovenous malformations. *Journal of NeuroInterventional Surgery* 2012;4(5):325-330.

139. Humar A, Michaels M, AST I, Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. *American Journal of Transplantation* 2006;6(2):262-274.

140. Rundback JH, Sacks D, Kent KC, et al. Guidelines for the reporting of renal artery revascularization in clinical trials. *Journal of Vascular and Interventional Radiology.* 2003;14(9 Pt2):S477-S492.

141. Higashida RT, Meyers PM, Phatouros CC, et al. Reporting standards for carotid artery angioplasty and stent placement. *Stroke.* 2004;35(5):e112-e134.

142. Nedeltchev K, Pattynama PM, Biaminoo G, et al. Standardized definitions and clinical endpoints in carotid artery and supra-aortic trunk revascularization trials. *Catheterization and Cardiovascular Interventions* 2010;76(3):333-344.

143. Banovac F, Buckley DC, Kuo WT, et al. Reporting standards for endovascular treatment of pulmonary embolism. *Journal of Vascular and Interventional Radiology.* 2010;21(1):44-53.

144. Meyers PM, Schumacher HC, Higashida RT, et al. Reporting standards for endovascular repair of saccular intracranial cerebral aneurysms. *Stroke.* 2009;40(5):e366-e379.

145. Higashida RT, Furlan AJ, Roberts H, et al. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. *Stroke.* 2003;34(8):e109-e137.

146. Rao SV, Eikelboom J, Steg PG, et al. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. *American Heart Journal* 2009;158(6):881-886.

147. Keyerleber MA, McEntee MC, Farrelly J, et al. Completeness of reporting of radiation therapy planning, dose, and delivery in veterinary radiation oncology manuscripts from 2005 to 2010. *Veterinary Radiology & Ultrasound.* 2012;53(2):221-230.

148. Mohler R, Kopek S, Meyer G. Criteria for reporting the development and evaluation of complex interventions in healthcare: revised guideline (CReDECI 2). *Trials.* 2015;16(204):1-9.

149. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurology* 2013;12(8):822-838.

150. Matcham J, Julious S, Pyke S, et al. Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry-sponsored clinical trials. *Pharmaceutical Statistics.* 2011;10(1):70-73.

151. Colbert AP, Spaulding K, Larsen A, et al. Electrodermal activity at acupoints: literature review and recommendations for reporting clinical trials. *Journal of Acupuncture and Meridian Studies.* 2011;4(5-13).

152. Dougados M, Simon P, Braun J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. *Annals of the Rheumatic Diseases* 2011;70(2):249-251.

153. Staquet M, Berzon R, Osoba D, et al. Guidelines for reporting results of quality of life assessments in clinical trials. *Quality of Life Research* 1996;5(5):496-502.

154. Agarwal S, Lefevre AE, Labrique AB. A call to digital health practitioners: New guidelines can help improve the quality of digital health evidence *JMIR Mhealth Uhealth.* 2017;5(10):e136.

155. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *Ann of Internal Medicine.* 2010;152(11):726-732.